Altria Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MO research report →
Range $58 – $85
Price Chart
About the company
Operating across the United States through its subsidiaries, Altria Group, Inc. is a prominent manufacturer and marketer of both combustible and oral tobacco items. Its portfolio features cigarettes, primarily under the iconic Marlboro brand, alongside cigars and pipe tobacco mainly offered as Black & Mild.
- CEO
- Salvatore Mancuso
- IPO
- 1985
- Employees
- 5,900
- HQ
- Richmond, VA, US
AI snapshot
Six angles, distilled from the data.
The stock is in a strong multi-month uptrend and remains above its 200-day moving average, with price pressing near the 52-week high. That keeps the regime constructive, though the move is extended after a steady climb from the mid-50s low to the high-70s area.
Street sentiment is constructive but not unanimous: consensus sits at Buy, with 16 Buy, 9 Hold, and 1 Sell ratings. The target picture has moved higher, with a 73.8 consensus target and a 83 median, while recent upgrades from major firms point to improving confidence even as one underperform view remains.
Earnings momentum is mixed but still positive, with 5 of the last 8 quarters beating estimates. Next-year EPS is modeled at 5.922 versus 4.85 TTM, so shareholders should watch whether pricing power and volume stability keep supporting that path after the latest 1.52 versus 1.51 beat.
The pattern leans to net selling, but most recent activity is dominated by awards and vesting-related entries rather than clear discretionary signals. The only notable open-market buy was 1,500 shares by a director, while two director sales in May outweighed it; the CEO and several directors also received large awards.
Profitability remains elite, anchored by a 61.24% operating margin and 39.33% net margin. Growth is modest but positive, with revenue up 3.6% and earnings up 6.7% year over year, while free cash flow reached $9.506 billion on just $216 million of capex.
MO wins on cash generation, margin durability, and defensive stability, but the market still prices in a mature tobacco profile rather than growth. At 14.26x earnings, it screens as a lower-multiple consumer staples name versus the broader market, with leverage still a watchpoint.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $124.54B
- P/E
- 15.40
- Fwd P/E
- 13.14
- PEG
- -2.02
- P/S
- 5.83
- P/B
- -56.02
- EV/EBITDA
- 12.13
- Div Yield
- 5.74%
- Gross Margin
- 69.93%
- Op Margin
- 51.90%
- Net Margin
- 38.10%
- ROE
- -279.72%
- ROIC
- 30.95%
Latest fiscal year · YoY change
- Revenue
- $20.14B-1.5%
- Gross Profit
- $14.54B+1.2%
- Op Income
- $9.90B
- Net Income
- $6.95B-38.3%
- EPS
- $4.11-37.2%
- OCF Growth
- +6.1%
- FCF Growth
- +5.4%
- 52W High
- $79.97
- 52W Low
- $54.70
- 50D MA
- $72.87
- 200D MA
- $69.92
- Beta
- 0.46
- RSI (14)
- 51
- Avg Volume
- 8.03M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Altria posted solid Q3 2026 results led by 4.8% adjusted EPS growth, stronger smokeable profits, and continued on! pouch expansion, and it raised full-year EPS guidance.· October 29, 2026
- Adjusted diluted EPS rose 4.8% in Q3 and 5.1% in the first 9 months.
- Smokeable products OCI increased 3.9% to $3.1 billion in Q3; margins expanded to 64.5%.
- on! shipment volume rose 13.3% to 47.8 million cans in Q3, and Helix expanded on! PLUS nationally with new flavors.
- Management raised full-year adjusted EPS guidance to $5.66-$5.74, up from a 2025 base of $5.42.
- The board authorized a $1 billion expansion of share repurchases and Altria increased its quarterly dividend by 4.7% to $1.11 per share.
Altria said adjusted diluted EPS increased 4.8% in the third quarter and 5.1% for the first 9 months. Adjusted operating companies income in smokeable products rose 3.9% to $3.1 billion in Q3 and 4.1% to $8.8 billion in the first 9 months, with adjusted OCI margins of 64.5% and 64.8%, respectively. Oral tobacco adjusted OCI fell 3.7% to $443 million in Q3 and 4% to $1.3 billion in the first 9 months, while oral tobacco margins were 66.4% and 66.8%. Reported domestic cigarette volumes declined 2.9% in Q3 and 2.8% in the first 9 months; on an adjusted basis, management estimated declines of 4% and about 5% for the industry. The company raised 2026 adjusted EPS guidance to $5.66-$5.74, implying 4.5% to 6% growth versus a 2025 base of $5.42.
Salvatore Mancuso framed the quarter as evidence that Altria’s portfolio strategy is working, with premium Marlboro support, discount participation through Basic, and continued investment in smoke-free growth. He emphasized that on! is gaining scale in a competitive nicotine pouch market and that the company is building long-term equity through expanded flavors, better retail visibility, and consumer-brand experiences like the on!vitational. He was also optimistic about the regulatory backdrop, saying the FDA’s planned PMTA rule changes and tighter illicit enforcement could create a more predictable path for legal smoke-free products.
Heather Newman highlighted strong execution across the business and pointed to the balance between profitability and investment. She cited 4.8% adjusted EPS growth in Q3, smokeable OCI of $3.1 billion, and oral tobacco OCI of $443 million, while noting margins remained strong at 64.5% in smokeables and 66.4% in oral tobacco. She also detailed capital returns: more than $6 billion returned to shareholders in the first 9 months, including $5.3 billion in dividends and $735 million in share repurchases, plus a 4.7% dividend increase to $1.11 per share and a $1 billion boost to the buyback authorization; debt-to-EBITDA was 1.9x at September 30.
Analysts pressed management on resilient cigarette volumes, guidance upside, duty drawback timing, NJOY ACE’s return, and the pace of on! growth relative to scanner data. Management said cigarette resilience is partly tied to consumers shifting from illicit e-vapor and to better enforcement, while Cowboy Cut is meant to be a premium Marlboro option that helps retain value-sensitive smokers. On on!, management said some of the quarterly volume difference versus scanner data reflects pipeline inventory and measurement noise around cans versus pouches, and on NJOY ACE it said the patent issue has been worked around but the company has not announced timing for a return; any re-entry would be disciplined and aimed at profitability.
The bull case from the call is that Altria is still producing earnings growth while defending cigarette profitability and expanding its smoke-free platform. Management sounded confident that on! PLUS, new flavors, better retail execution, and improving enforcement against illicit vapes can support longer-term growth and more predictable category economics.
The main risks discussed were continued macro pressure on smokers, elevated competition in both cigarettes and nicotine pouches, and regulatory uncertainty around the FDA’s PMTA process. Management also acknowledged that oral tobacco volume growth is being affected by MST declines, that NJOY remains absent from the market for now, and that the e-vapor category is still dominated by illicit products.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 1.66B
- Float Shares
- 1.66B
of shares held by institutions
2,659 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 10, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 13, 26 | Filing → |
| Sheri BiggsHouse · SC03 | Sell | Mar 19, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 4, 25 | Filing → |
| Pete SessionsHouse · TX17 | Sell | Sep 10, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Mar 20, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 13, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 10, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 10, 24 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Sell | Jan 10, 24 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Buy | Jan 11, 24 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Sell | Jan 16, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 160.98M | ▲ 1.90M |
| Blackrock, Inc. | 122.73M | ▼ 3.34M |
| Vanguard Capital Management LLC | 109.27M | ▲ 232.17K |
| State Street Corp | 70.63M | ▲ 432.75K |
| Charles Schwab Investment Management Inc | 59.12M | ▲ 4.84M |
| Sixth Street Partners Management Company, L.P. | 59.12M | ▲ 59.12M |
| Capital Research Global Investors | 58.39M | ▼ 266.50K |
| Geode Capital Management, LLC | 49.05M | ▲ 1.33M |
| Vanguard Portfolio Management LLC | 33.96M | ▲ 236.79K |
| Morgan Stanley | 22.77M | ▲ 66.28K |
| Ameriprise Financial Inc | 22.05M | ▲ 544.33K |
| Capital World Investors | 18.25M | ▼ 231.67K |
Held by 1,386 ETFs
Biggest fund positions in MO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 14, 26 | Patterson Katie F | other | 1,268 |
| Sep 9, 26 | McQUADE KATHRYN B. | buy | 1,500 |
| Aug 27, 26 | Presley Steven W. | other | 0 |
| May 26, 26 | KELLY ENNIS DEBRA J | sell | 5,790 |
| May 26, 26 | Strahlman Ellen R | sell | 2,000 |
| May 14, 26 | Strahlman Ellen R | other | 2,571 |
| May 14, 26 | Stoddart Richard S | other | 2,571 |
| May 14, 26 | Clarke Ian L.T. | other | 2,571 |
| May 14, 26 | Connelly Marjorie Mary | other | 2,571 |
| May 14, 26 | KELLY ENNIS DEBRA J | other | 2,571 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MO coverage
Recent articles, reports, and earnings notes.

Altria Group (MO): Cash Flow Strength vs. Growth Drag
Altria is generating strong cash flow and steady EPS growth, but cigarette volume declines and a still-developing smoke-free strategy keep the stock at Hold. The shares trade near fair value, with income and execution in new nicotine products driving the next leg.

Altria Group, Inc. (MO) rises 5% on earnings beat
Altria Group, Inc. (MO) rises after a strong Q3 update that topped EPS estimates, lifted full-year guidance, and expanded share repurchases. The move came on above-average volume and pushed the stock to a fresh 52-week high, reinforcing the company’s income and defensive appeal.

Altria Group (MO): Cash Flow, Pouches, and Cigarette Decline
Altria combines strong cash generation and Marlboro pricing power with a growing on! pouch franchise, but cigarette volume declines and leverage keep the stock in Hold territory.
Want a deeper read on MO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
3 Neglected High-Yield Dividend Stocks Paying 5% or More
247wallst.com · Nov 20
Is Altria's 5.6% Dividend Yield Too Good to Be True Heading Into 2027?
fool.com · Nov 20
The Roth IRA Mistake That Turns a 59-Year-Old’s $6,325 a Month in Tax-Free Dividends Into a Tax Bill
247wallst.com · Nov 20
Undercovered Dozen: Annaly, Vertiv, Intuitive Machines And More
seekingalpha.com · Nov 20
Here's How Much $10,000 Invested in Altria Stock Could Pay in Dividends Over the Next Decade
fool.com · Nov 20
MO Lifts 2026 EPS Outlook as Pricing Offsets Cigarette Volume Declines
zacks.com · Nov 19
MO Stock Jumps 10.3% in 3 Months as Pricing Power Supports Earnings
zacks.com · Nov 19
Is MO Stock a Buy Now as Earnings Strength Meets Valuation Pressure?
zacks.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 13, 2026 · Live quote · Not investment advice